Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,394 · cited 1×
“Although traditional chemotherapies have a response rate of less than 10% and a 6-month PFS (PFS-6) of about 15%, the fi rst reported trial of bevacizumab and irinotecan for GBM reported a 57% initial partial response or better and a PFS-6 of 46% [ 23 ].”
BackgroundPhase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2309 · Cited by 1,078
Brandes, A. A., Franceschi, E., Tosoni, A., Blatt, V., Pession, A., Tallini, G., Bertorelle, R., Bartolini, S., Calbucci, F., Andreoli, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8163 · Cited by 840 · cited 3×
“Brandes et al. [ 7 ] reported on the incidence of pseudoprogression in patients enrolled in a clinical trial evaluating radiotherapy plus daily temozolomide followed by adjuvant temozolomide, similar to the regimen described above.”
BackgroundMethodInfluentialBevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
Norden, A. D., Young, G. S., Setayesh, K., Muzikansky, A., Klufas, R., Ross, G. L., Ciampa, A. S., Ebbeling, L. G., Levy, B., Drappatz, J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000304121.57857.38 · Cited by 801 · cited 1×
“gadolinium [ 27 ]. By traditional response criteria [2], these patients still have stable disease or even a partial tumor response.”
BackgroundKumar, A. J., Leeds, N. E., Fuller, G. N., Van Tassel, P., Maor, M. H., Sawaya, R. E., & Levin, V. A. (2000) · Radiology · doi:10.1148/radiology.217.2.r00nv36377 · Cited by 669
Taal, W., Brandsma, D., de Bruin, H. G., Bromberg, J. E., Swaak‐Kragten, A. T., Sillevis Smitt, P. A. E., van Es, C. A., & van den Bent, M. J. (2008) · Cancer · doi:10.1002/cncr.23562 · Cited by 465 · cited 3×
“Taal et al. [ 6 ] reported on 85 newly diagnosed patients with malignant glioma (68 GBM, 17 anaplastic gliomas) treated with the same regimen described by Chamberlain et al. [5•].”
BackgroundMethodInfluentialClinical Applications of PET in Brain Tumors
Chen, W. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.037689 · Cited by 449
Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen, W., Cloughesy, T. F., Kamdar, N. V., Satyamurthy, N., Bergsneider, M., Liau, L. M., Mischel, P. S., Czernin, J., Phelps, M. E., & Silverman, D. H. S. (2005) · PubMed · Cited by 437
Terakawa, Y., Tsuyuguchi, N., Iwai, Y., Yamanaka, K., Higashiyama, S., Takami, T., & Ohata, K. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.048082 · Cited by 419 · cited 1×
“Terakawa et al. [ 19 ] evaluated PET using 11 Cmethionine, an amino acid analogue, and found it to have a sensitivity and specifi city of about 75% each.”
MethodHu, L. S., Baxter, L. C., Smith, K. A., Feuerstein, B. G., Karis, J. P., Eschbacher, J. M., Coons, S. W., Nakaji, P., Yeh, R. F., Debbins, J., et al. (2009) · American Journal of Neuroradiology · doi:10.3174/ajnr.a1377 · Cited by 396
Prados, M. D., Chang, S. M., Butowski, N., DeBoer, R., Parvataneni, R., Carliner, H., Kabuubi, P., Ayers-Ringler, J., Rabbitt, J., Page, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9639 · Cited by 378 · cited 1×
“As shown by others [8, 9 ], patients with methylated MGMT promoter status had a longer median overall survival (43.6 months vs 16.8 months).”
ResultSelf-citationEarly necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma
Chamberlain, M. C., Glantz, M. J., Chalmers, L., Van Horn, A., & Sloan, A. E. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9241-y · Cited by 343
Ricci, P. E., Karis, J. P., Heiserman, J. E., Fram, E. K., Bice, A. N., & Drayer, B. P. (1998) · PubMed · Cited by 341
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Pope, W. B., Lai, A., Nghiemphu, P., Mischel, P., & Cloughesy, T. F. (2006) · Neurology · doi:10.1212/01.wnl.0000208958.29600.87 · Cited by 271 · cited 1×
“In both of these trials, gadolinium-enhanced MRI was used as the basis for determining response; the improvements seen on gadolinium-enhanced MRI due to bevacizumab have been seen as early as 18 days after initiating therapy [ 25 ].”
ResultMRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Chamberlain, M. C. (2006) · Neurology · doi:10.1212/01.wnl.0000250628.10420.d8 · Cited by 264
Raymond, E., Brandes, A. A., Dittrich, C., Fumoleau, P., Coudert, B., Clement, P. M. J., Frenay, M., Rampling, R., Stupp, R., Kros, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9235 · Cited by 227 · cited 1×
“In reality, however, it is clear that there is progression of infi ltrative tumor that correlates with the neurologic decline noted (Fig. 2). First noted in patients treated with bevacizumab, a similar situation was seen in a clinical trial of imatinib, another drug with antiangiogenic properties, in recurrent maligna…”
ResultCloughesy, T. F., Prados, M. D., Wen, P. Y., Mikkelsen, T., Abrey, L. E., Schiff, D., Yung, W. K., Maoxia, Z., Dimery, I., & Friedman, H. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.2010b · Cited by 144
Clinical and radiographic features of peritumoral infarction following resection of glioblastoma
Ulmer, S., Braga, T. A., Barker, F. G., Lev, M. H., González, R., & Henson, J. W. (2006) · Neurology · doi:10.1212/01.wnl.0000242894.21705.3c · Cited by 135 · cited 1×
“Postictal changes on MRI can also transiently increase enhancement [3], as can postsurgical changes [ 4 ].”
BackgroundDifferentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET
Zhang, X., & Weian, C. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9286-y · Cited by 51 · cited 1×
“Another novel tracer, 13 N-ammonia, has also shown early promise, albeit in a single report with only seven patients [ 21 ].”
Background
Cited by
A survey of MRI-based medical image analysis for brain tumor studies
Bauer, S., Wiest, R., Nolte, L.-P., & Reyes, M. (2013) · Physics in Medicine and Biology · doi:10.1088/0031-9155/58/13/r97 · Cited by 1,036
“However, this approach carries some important limitations (Clarke and Chang 2009).”
BackgroundPseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma
Hygino da Cruz, L. C., Rodriguez, I., Domingues, R. C., Gasparetto, E. L., & Sorensen, A. G. (2011) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2397 · Cited by 545
Zhou, J., Tryggestad, E., Wen, Z., Lal, B., Zhou, T., Grossman, R., Wang, S., Yan, K., Fu, D.-X., Ford, E., et al. (2011) · Nature Medicine · doi:10.1038/nm.2268 · Cited by 526
Pseudoprogression and pseudoresponse in the treatment of gliomas
Brandsma, D., & van den Bent, M. J. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328332363e · Cited by 378
Perfusion MRI: The Five Most Frequently Asked Clinical Questions
Essig, M., Nguyen, T. B., Shiroishi, M. S., Saake, M., Provenzale, J. M., Enterline, D. S., Anzalone, N., Dörfler, A., Rovira, À., Wintermark, M., et al. (2013) · American Journal of Roentgenology · doi:10.2214/ajr.12.9544 · Cited by 344
Metadata
- Authors
- Clarke, J. L., & Chang, S.
- Venue
- Current Neurology and Neuroscience Reports
- Published
- 2009-04-04
- Volume
- 9
- Issue
- 3
- Pages
- 241-246
- ISSN
- 1528-4042 (ISSN-L)
- 1534-6293
- OpenAlex
- W2078646447
- Cited by
- 170
- References
- 24
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.